Researchers have developed a gene therapy for sickle cell anemia that allowed laboratory animals and human tissue samples to produce normal red blood cells instead of the misshapen ones that are the hallmark of the disease. The therapy involves implanting a gene that neutralizes the function of hemoglobin S, which is responsible for the malformed blood cells. The researchers plan to test the treatment on humans next year, pending regulatory approval.

Related Summaries